Cyclacel Pharmaceuticals Financials

CYCC Stock  USD 0.33  0.00  0.000003%   
Based on the key indicators related to Cyclacel Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Cyclacel Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At present, Cyclacel Pharmaceuticals' Total Liabilities is projected to decrease significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.7 M, whereas Total Assets are forecasted to decline to about 7.5 M. Key indicators impacting Cyclacel Pharmaceuticals' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.780.82
Notably Down
Very volatile
Investors should never underestimate Cyclacel Pharmaceuticals' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Cyclacel Pharmaceuticals' cash flow, debt, and profitability to make informed and accurate decisions about investing in Cyclacel Pharmaceuticals.

Net Income

(27.24 Million)

  
Understanding current and past Cyclacel Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cyclacel Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Cyclacel Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Cyclacel Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cyclacel Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cyclacel Pharmaceuticals' management manipulating its earnings.

Cyclacel Pharmaceuticals Stock Summary

Cyclacel Pharmaceuticals competes with Ikena Oncology, Ovid Therapeutics, Connect Biopharma, Edgewise Therapeutics, and Rezolute. Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS23254L6039
CUSIP23254L306 23254L603 23254L405 23254L801 23254L108 98389F309
LocationNew Jersey; U.S.A
Business Address200 Connell Drive,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.cyclacel.com
Phone908 517 7330
CurrencyUSD - US Dollar

Cyclacel Pharmaceuticals Key Financial Ratios

Cyclacel Pharmaceuticals Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets36.8M42.6M27.5M8.8M7.9M7.5M
Retained Earnings(366.1M)(385.0M)(406.2M)(428.3M)(385.5M)(404.7M)
Total Liab3.5M5.3M12.0M8.2M7.4M14.1M
Other Current Liab2.0M3.2M4.8M4.6M4.2M3.4M
Net Debt(32.3M)(36.5M)(18.2M)(3.3M)(3.0M)(3.2M)
Accounts Payable514K2.1M2.6M3.5M4.1M2.2M
Cash33.4M36.6M18.3M3.4M3.9M3.7M
Other Current Assets750K4.4M6.1M1.1M1.3M1.3M
Total Current Assets35.5M40.9M24.4M7.4M6.7M6.4M
Common Stock6K10K4.5M1K1.2K1.1K
Net Receivables1.3M3.7M5.6M2.9M3.4M2.7M
Inventory703K684K577K(5.6M)(5.1M)(4.8M)
Net Tangible Assets11.7M33.3M37.3M15.5M17.8M23.9M
Net Invested Capital33.3M37.3M20.0M607K546.3K519.0K
Net Working Capital33.0M35.6M17.0M(717K)(645.3K)(613.0K)
Capital Stock6K10K4.5M1K1.2K1.1K

Cyclacel Pharmaceuticals Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense677K997K291K2.0M2.3M2.4M
Operating Income(10.6M)(22.9M)(27.7M)(25.5M)(29.3M)(30.7M)
Ebit(10.6M)(22.7M)(27.7M)(25.5M)(29.3M)(30.7M)
Research Development4.8M15.5M20.3M19.2M17.2M8.8M
Ebitda(10.6M)(22.7M)(27.9M)(25.4M)(29.2M)(30.7M)
Income Before Tax(9.7M)(22.7M)(25.9M)(25.6M)(29.4M)(30.9M)
Net Income(8.4M)(18.9M)(21.2M)(22.6M)(25.9M)(27.2M)
Income Tax Expense(1.2M)(3.8M)(4.7M)(3.0M)(2.7M)(2.6M)
Tax Provision(1.2M)(3.8M)(4.7M)(4.2M)(3.7M)(3.9M)
Interest Income42K16K210K365K328.5K344.9K
Net Interest Income42K16K210K365K419.8K440.7K

Cyclacel Pharmaceuticals Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash21.5M3.2M(18.2M)(15.0M)(13.5M)(12.8M)
Free Cash Flow(8.0M)(18.6M)(20.8M)(16.1M)(18.5M)(19.5M)
Other Non Cash Items(21.3M)(3.5M)(967K)227.0K204.3K214.5K
Capital Expenditures10K96K27K7K5.4K5.1K
Net Income(8.4M)(18.9M)(21.2M)(22.6M)(25.9M)(27.2M)
End Period Cash Flow33.4M36.6M18.3M3.4M3.9M3.7M
Change To Netincome428K430K1.3M1.5M1.8M1.9M
Investments(96K)(27K)(7K)(6K)(5.4K)(5.7K)

Cyclacel Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cyclacel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Cyclacel Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cyclacel Pharmaceuticals competition to find correlations between indicators driving Cyclacel Pharmaceuticals's intrinsic value. More Info.
Cyclacel Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Cyclacel Pharmaceuticals' Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cyclacel Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Cyclacel Pharmaceuticals Systematic Risk

Cyclacel Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cyclacel Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Cyclacel Pharmaceuticals correlated with the market. If Beta is less than 0 Cyclacel Pharmaceuticals generally moves in the opposite direction as compared to the market. If Cyclacel Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cyclacel Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cyclacel Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Cyclacel Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Cyclacel Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cyclacel Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Cyclacel Pharmaceuticals growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.006471

At present, Cyclacel Pharmaceuticals' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.

Cyclacel Pharmaceuticals February 1, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cyclacel Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cyclacel Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cyclacel Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Cyclacel Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cyclacel Pharmaceuticals's daily price indicators and compare them against related drivers.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Technical Analysis
Check basic technical indicators and analysis based on most latest market data